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ABSTRACT
There has been significant progress in the understanding of the pathology and molecular biology 
of rare ovarian cancers, which has helped both diagnosis and treatment. This paper provides an 
update on recent advances in the knowledge and treatment of rare ovarian cancers and identifies 
gaps that need to be addressed by further clinical research. The topics covered include: low-grade 
serous, mucinous, and clear cell carcinomas of the ovary. Given the molecular heterogeneity and 
the histopathological rarity of these ovarian cancers, the importance of designing adequately 
powered trials or finding statistically innovative ways to approach the treatment of these rare 
tumors has been emphasized. This paper is based on the Rare Ovarian Tumors Conference 
for Young Investigators which was presented in Tokyo 2015 prior to the 5th Ovarian Cancer 
Consensus Conference of the Gynecologic Cancer InterGroup (GCIG).
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INTRODUCTION
At the Rare Ovarian Tumors Conference held in Tokyo 2015 prior to the 5th Ovarian Cancer 
Consensus Conference of the Gynecologic Cancer InterGroup (GCIG), young investigators 
addressed an update on recent advances in the knowledge and treatment of rare ovarian 
cancers, including low-grade serous, mucinous, and clear cell carcinomas of the ovary.
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LOW-GRADE SEROUS CARCINOMA (LGSC)
1. Background
Recent studies have identified low-grade and high-grade serous carcinomas (HGSC) 
as 2 distinct entities and the new edition of the World Health Organization (WHO) 
classification, published in 2014, has adopted this binary classification. Traditional 3-tiered 
grading of serous carcinoma had limited significance in terms of prognosis, management 
strategies, and biology, whereas the 2-tier system well reflects the molecular pathogenesis, 
clinicopathologic features, and epidemiology. These criteria for grading, established by 
Malpica et al. [1], have now been widely accepted. LGSC defined as serous carcinoma 
composed of uniform cells showing mild to moderate nuclear atypia and fewer mitotic 
figures (12 or less, and in general, mostly 2 to 3 per 10 high power fields [HPFs]), is a rare 
neoplasm accounting for 5%–10% of all ovarian serous carcinomas. Very rarely, LGSC may 
give rise to HGSC or undifferentiated carcinoma [2].
2. Understanding the difference between LGSC and HGSC
LGSC and HGSC differ distinctly in presentation, histogenesis, treatment strategies, 
and outcome (Table 1). The former is characterised by younger age, and paradoxically, 
poor response to conventional chemotherapy [3-7]. It is mitotically less active, and 
immunohistochemically shows a low Ki-67 labelling index. Since TP53 is typically intact, 
TP53 immunostaining shows wild-type pattern, aiding distinction of LGSC from HGSC. 
KRAS, BRAF, or ERBB2 mutations are common in contrast to HGSC, which is characterised 
nearly uniform loss of TP53 function due to mutation or deletion, associated with significant 
chromosomal instability and decreased overall survival (OS) [8].
HGSC is considered to rise de novo in association with serous tubal intraepithelial carcinoma 
(STIC). On the other hand, LGSC appears to have a close phenotypic relationship to 
serous borderline tumors (SBT), particularly of the micropapillary type, because of similar 
cytomorphology, occasional co-existence of both borderline and low-grade components, 
and overexpression of CDKN1A and other TP53 modulated genes [9] indicating the existence 
of adenoma-carcinoma sequence [10]. Therefore, the revised WHO classification (2014) 
specifically defines micropapillary SBT as non-invasive LGSC.
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Table 1. Differentiating low- and high-grade serous carcinoma
Feature LGSC HGSC Source
Nuclear atypia Uniform Pleomorphic [1]
Form Oval/round Variable [1]
Size and shape Uniform Variable (>3:1) in size [1]
Nucleoli May exist Present [1]
Mitotic index/10 HPFs ≤12 >12 [1]
Precursor SBT STIC [7]
Incidence 4%–10% >85% [6]
Median age Younger, <50 yr Older, >50 yr [6]
Stage at presentation Early in about 40% Advanced in 70%–80% [6]
Clinical course Indolent Aggressive [6]
Response to chemotherapy Usually poor Good but with high recurrence rate [3–5]
Chromosomal instability Low High [13]
Gene mutation KRAS, BRAF, and ERBB2 TP53 [8]
5-yr survival 50%–60% 30%–40% [4,6,7,15]
HGSC, high-grade serous carcinoma; HPF, high power field; LGSC, low-grade serous carcinoma; SBT, serous borderline tumor; STIC, serous tubal intraepithelial 
carcinoma.
SBT shares a common high KRAS mutation rate with LGSC (20%–40% of cases), and much 
more frequently shows BRAF mutations compared with LGSC (30%–50% vs. 0%–30%) 
especially in advanced stages [8-11]. Deletion of tumor-suppressor function of miR-34a and 
CDKN2A/B has been suggested to be implicated in the progression of SBT to LGSC, although 
this finding remains to be confirmed by further evaluation [12]. The distinction between SBT 
and LGSC is critical for deciding on conservative or radical surgical management, since fertility 
is often a major concern in younger patients especially with bilateral disease [13]. A recent study 
has demonstrated that women below the age of 35 years with persistent disease at completion 
of initial therapy have a poorer outcome [14]. There has been a suggested association between 
an increased risk for developing LGSC in women who have a history of endometriosis [15].
3. Treatment targets
Traditional platinum-taxane combination chemotherapy has shown to have lower activity 
in LGSC compared to HGSC [5]. Commonly, primary cytoreductive surgery followed by 
adjuvant platinum based chemotherapy for advanced disease has been the standard practice 
in many countries despite limited evidence of benefit from chemotherapy [16-19]. Targeted 
therapies have, however, shown considerable promise, mainly in small non-randomized 
trials. Bevacizumab; Grisham et al. [20] performed a retrospective review of 17 patients 
who were treated with bevacizumab, 15 of whom were treated with combinations and 2 
with bevacizumab alone. A partial response was obtained in 40% of the patient group (95% 
confidence interval [CI]=16.3%–67.7%). Similar results were obtained in a retrospective 
review performed by Schmeler et al. [21], with a response rate of 41% in a group of 21 
patients. The value of bevacizumab in first-line treatment of serous ovarian cancers has been 
demonstrated in 2 phase III randomised studies; the GCIG International Collaboration on 
Ovarian Neoplasms 7 (ICON7) trial and the complementary Gynecologic Oncology Group 
study 0218 (GOG-0218) with promising results, however there were limited data in lower 
grade cancers (Table 2) [22,23]. For recurrent disease, surgery remains the most effective 
intervention, and should be performed whenever possible. Hormonal therapy; LGSC express 
higher levels of estrogen receptor (ER), progesterone receptor (PR), and E-cadherin than 
HGSC, suggesting the possibility of these receptors as potential targets of therapy [24] 
and treatment with tamoxifen and letrozole has been shown to provide clinical benefit in 
epithelial ovarian cancers overall [25,26]. A retrospective review of hormonal intervention 
suggested moderate anti-tumor activity in cases of recurrent LGSC with the median time 
to progression (TTP) being 7.4 months (95% CI=6.0–8.9 months), and that patients with 
both ER and PR double positive tumors had longer TTP than those who were PR negative. 
The study concluded that the stability of ER and PR in LGSC in the long term however was 
questionable and hence further studies are required [27]. Vemurafenib; the presence of 
V600E BRAF mutations, although low in incidence, is associated with an improved prognosis 
and is more frequently seen in early stage disease [28]. Treatment with vemurafenib, a 
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Table 2. Bevacizumab in low- and high-grade serous carcinoma
Trial No. of patients HR
GOG-0218 [22]
Low-grade 235 0.59
High-grade 842 0.70
ICON7 [23]
Grade 1 97 0.76
Grade 2 317 0.77
Grade 3 1,094 0.81
GOG, Gynecologic Oncology Group; HR, hazard ratio; ICON7, International Collaboration on Ovarian Neoplasms 7.
BRAF inhibitor specific for V600E mutations has shown long term partial responses with 
improvement in both CA125 levels and in symptom control [29]. Mitogen-activated protein 
kinase kinase (MEK) inhibitors; Selumetinib (AZD6244, ARRY-142886) an orally available 
small molecule inhibitor of the MEK pathway was tested in a phase II clinical trial of 52 
patients with LGSC. The median progression-free survival (PFS) was 11 months with a 
response rate of 15% (90% CI=7.9%–26.1%). The response to selumetinib did not appear to 
be related to RAS/RAF mutation status owing to significant tumor heterogeneity, and other 
factors that may contribute to pathway activation [30]. A randomized phase II/III trial is 
currently underway for trametinib, a MEK inhibitor, in recurrent or progressive low-grade 
serous ovarian cancer (GOG281), comparing the effectiveness of trametinib to chemotherapy 
chosen by the physician [31]. The MEK inhibitor in low-grade serous ovarian cancer (MILO) 
trial, an international, randomized phase III study of binimetinib or a chemotherapy chosen 
by a physician in patients with recurrent or persistent LGSC, was closed earlier after a 
planned interim analysis which showed that the hazard ratio for PFS crossed the predefined 
futility boundary [32]. Insulin-like growth factor 1 (IGF-1) pathway; IGF-1 is overexpressed 
in LGSC compared to SBT and HGSC and IGF-1 and Akt activation may be a potential 
drug target in the future [33]. Phase II trials are currently underway with the anti-IGF-1R 
monoclonal antibodies figitumumab (CP-751871) and ganitumab (AMG479) in epithelial 
ovarian cancer.
4. Take home message
As LGSC demonstrates distinct clinicopathologic and molecular features, it should 
be distinguished from HGSC in future clinical trials with translational components 
incorporated into their design. International cooperation will be required to establish 
strategies employing targeted agents as well as defining effective prognostic and predictive 
biomarkers. Finally, gynaecologic oncologists should be aware of the rare coexistence or 
progression to HGSC in cases of LGSC or SBT which can be a pitfall in management.
MUCINOUS CARCINOMA
1. Background
Ovarian mucinous carcinoma (OMC) is defined as an epithelial tumor with frank invasion 
(the largest invasive area equal to or greater than 5 mm) composed of gastrointestinal-type 
cells containing intracytoplasmic mucin. Recent studies have revealed that primary OMCs are 
much less common than previously reported (2%–3% of primary ovarian carcinomas), and 
that those reported as primary OMCs in the past likely included some metastatic tumors as 
well as mucinous borderline tumors [34,35]. There are 2 types of invasion in OMCs, expansile 
(or confluent glandular) and infiltrative, which may coexist in a single tumor (Table 3). The 
pathological distinction of pattern of invasion is important, as there is significant difference 
in prognosis between those with confluent and infiltrative type of invasion. Majority of 
OMCs are with expansile invasion, almost always stage I, and are usually associated with a 
favourable prognosis [36-38]. In contrast, about 80% of OMCs with infiltrative invasion are 
stage I, 20% of which recur. Recurrences tend to occur within 3 years of diagnosis and do not 
respond to chemotherapy or radiotherapy.
Distinction between primary OMCs and metastatic tumors may be pathologically challenging, 
although careful gross examination and thorough sampling of the tumor with assistance of 
immunohistochemistry in certain situation could lead to a correct diagnosis in many of the 
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cases. Those with bilaterality, small size (<10 cm in diameter), high-stage, and an infiltrative 
invasion should raise suspicion for metastatic tumors [34, 39-41]. The pathological features 
that favour primary mucinous tumors include: size >10 cm in diameter, multilocular cystic 
and/or solid tumor without multiple nodules, smooth external surface, expansile pattern of 
invasion, complex papillary pattern, coexistence of borderline or benign components, an 
association with a teratoma, endometriosis, adenofibroma, Brenner tumor, or mural nodule. 
Because OMCs typically form large cystic masses with or without solid component and are 
frequently admixed with benign and borderline components, sampling is crucial for accurate 
pathological diagnosis of OMCs. The number of the sections recommended is at least one per 
centimetre of maximum tumor dimension for tumor smaller than 10 cm, and 2 sections per 
centimetre for larger tumors [41].
2. Dilemmas in diagnosis and management
A small portion of advanced-stage mucinous tumors of the ovary are primary in origin 
(20%) and most are metastatic tumors from the gastrointestinal tract (45%), pancreas 
(20%), cervix (13%), breast (8%), uterus (5%), or unknown (10%) [35]. Clinicians face great 
challenge in pathologically distinguishing a primary mucinous tumor of ovarian origin from 
a metastatic tumor. In this case, molecular and clinical features may aid in distinguishing 
the two (Table 4) [40-45]. A retrospective analysis of GOG182/ICON5 on independent 
review of 44 stage III/IV mucinous carcinomas of the ovary by 3 different pathologists, 
showed that median survival did not differ greatly between primary or metastatic groups. 
However, many of those mucinous carcinomas that were initially diagnosed as primary OMC 
appeared to be metastatic in origin [46].
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Table 3. Classification of mucinous tumors of the ovary
Type Subtype
Benign  
Cystadenoma
Cystadenofibroma
Borderline  
Borderline with intraepithelial atypia
Borderline with microinvasion <5 mm
Borderline with microinvasive carcinoma
Carcinoma (frank invasion ≥5 mm)  
Confluent type
Infiltrative type
Table 4. Differentiating mucinous carcinomas of primary vs. metastatic origin
Feature Primary Metastatic
Pathological pattern Intracellular mucin (>50%), in at least 90% of tumor cells 
Complex papillary pattern
Abundant extracellular mucin, in 50% or greater tumor volume 
Nodular pattern
Involvement Coexistence of borderline/benign mucinous component 
Expansile pattern of invasion
Ovarian surface involvement 
Hilar involvement 
Vascular invasion 
Extensive infiltrative pattern of invasion
Size and distribution Unilateral 
Size >10 cm
Bilateral 
Size <10 cm
Markers CA125 
CEA >25
Elevation may be present, although less than in colorectal primary 
cancers
Molecular alterations KRAS mutations: 43% 
BRAF mutations: 0% 
HER2 amplification: 18%
KRAS mutations: 30% 
BRAF mutations: 20% 
HER2 amplification: <1%
CEA, carcinoembryonic antigen; HER2, human epidermal growth factor receptor 2.
As most OMCs present with localized disease (more than 80% of OMCs are stage I at the 
time of diagnosis), the standard treatment for patients with early mucinous carcinomas is 
cytoreductive surgery with pathological evaluation accompanied by surgical staging and 
special attention to possible gastrointestinal sites of primary disease. Nodal staging is not 
required in stage IA/IB due to the almost absence of nodal involvement. In younger patients 
with unilateral early stage disease it is reasonable to consider fertility sparing surgery. 
Furthermore, there is no clear evidence to suggest that adjuvant chemotherapy is beneficial 
in the setting of early stage disease. There is limited evidence for the effectiveness of systemic 
therapy in late stage OMCs. Most notably, only 2%–7% of patients in large randomized 
controlled trials had mucinous carcinomas. A retrospective review by Winter et al. [47] which 
investigated the effects of platinum/paclitaxel post debulking surgery in the mucinous cancer 
group, showed a median OS of 14.8 months comparable to 45.1 months in the serous group. 
Mimicking Winter's study, results produced by the Groupe d'Investigateurs Nationaux Pour 
les Etudes des Cancers de l'Ovaire (GINECO), GOG, and GCIG group have yielded similar 
results (Table 5) [48-50].
Disappointing results with first line platinum-based chemotherapy in OMCs have prompted 
research into specific targeted therapy such as agents that act on the human epidermal 
growth factor receptor 2 (HER2)/neu, KRAS, or angiogenesis pathways. A phase III study of 
carboplatin/paclitaxel vs. oxaliplatin/capecitabine with or without bevacizumab showed hope 
that bevacizumab may delay progression; however, the study was stopped early due to poor 
accrual of patients [51]. Molecular characterisation of mucinous ovarian tumors has shown 
overexpression of HER2 in 19% of cases with perfect agreement on immunohistochemistry, 
fluorescence in situ hybridization (FISH), and chromogenic in situ hybridization (CISH) [52]. 
A higher incidence of HER2 overexpression in the Asian population has been postulated by 
Chay et al. [53], and whilst the impact of HER2 status on OS is yet to be clearly established, 
anti-HER2 therapy in combination with other agents may have a role in management [54,55].
3. Take home message
It is unfortunate that large trials for mucinous carcinomas in the international setting have 
been largely unsuccessful, and the best treatment is still unknown. As mucinous carcinomas 
have been shown to harbour a variety of molecular changes, the efficacy of single agent 
targeted therapy may be limited. Moreover, it is difficult to design adequately powered 
randomized controlled trials in cancers of such rare histological subtype. It will be important 
to use innovative trial designs to overcome this difficulty.
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Table 5. Comparison of OS and PFS in OMC compared to serous ovarian carcinoma
Study Median OS (mon) Median PFS (mon)
Winter et al. [47]
Serous 45.1 16.9
Mucinous 14.8 10.5
Alexandre et al. [48]
Serous 47.2 17.5
Mucinous 21.6 11.4
Tian et al. [49]
Serous 40.5 16.7
Mucinous 11.3 9.7
Mackay et al. [50]
Serous 40.8 16.1
Mucinous 14.6 7.6
OMC, ovarian mucinous carcinoma; OS, overall survival; PFS, progression-free survival.
CLEAR CELL CARCINOMA
1. Background
Ovarian clear cell carcinoma (OCCC) is a subtype of epithelial ovarian carcinoma which 
is distinct from HGSC, associated with poor prognosis in advanced stages and has been 
shown to be resistant to conventional platinum-based chemotherapy [56]. It accounts for 
5%–25% of epithelial ovarian cancers with a higher incidence seen in Eastern-Asian women. 
Women with OCCC usually present early with 57%–81% presentations in stage I or II, and are 
younger (median age 55 years) and the disease is commonly associated with endometriosis. 
Hypercalcaemia and an increased incidence of venous thrombotic events may occur [57].
Histological features of OCCC include a variety of growth patterns (micropapillary, 
tubulocystic, solid, and adenofibromatous), cell types (hobnail, clear cell, and oxyphilic), 
stromal changes (hyalinized, necrotic, hemorrhagic, and psammomatous calcification), 
and the presence of endometriosis, atypical endometriosis, and atypical proliferative clear 
cell tumors [58-60]. These histological features often co-exist in the one tumor. Serous or 
endometrioid carcinoma frequently demonstrates cytoplasmic clearing (clear cell change), 
which leads to difficulty in accurate diagnoses of OCCC. A mitotic count greater than 5 per 
10 HPFs is almost never encountered, with most tumors having mitotic counts between 0 
and 2 per 10 HPFs [59]. The tumor arises from endometriosis in 50%–70% of cases [58]. An 
adenofibromatous pattern is present in 20%–25% of cases, and stromal hyalinization is one 
of the characteristic features [58,59].
2. Molecular changes in OCCC and translational possibilities
The molecular pathogenesis of OCCC is less well characterised than HGSC, however many 
studies show that it harbors unique molecular features including the AT-rich interactive 
domain 1A (ARID1A) gene mutation, hepatocyte nuclear factor-1β (HNF-1β) overexpression, 
and the phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA) mutation (Table 6) [61,62]. 
ARID1A encodes a key component of the switch/sucrose nonfermentable (SWI/SNF) chromatin 
remodelling complex that regulates gene expression targeting multiple pathways that lead 
to tumorigenesis. It acts as a tumor-suppressor gene in OCCC and is seen in pre-neoplastic 
lesions leading to the speculation that this gene is implicated in the early transformation of 
endometriotic cells into cancer. It has been identified in up to 57% of cases of OCCC however 
no distinct phenotypical property has been identified that may contribute to increased survival 
[63-66]. HNF-1β is a transcription factor with predominant expression in liver, pancreas, and 
kidney and is known as a hallmark of OCCC. HNF-1β plays multiple roles in tumorigenesis and 
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Table 6. Summary of mutated genes in OCCC [61-75]
Type Gene Frequency of mutation (%)
Oncogene PIK3CA 54
KRAS 10
PPP2R1A 10
Tumor suppressor ARID1A 62
MLL3 15
ARID1B 8
ASXL1 8
CHD8 8
PIK3R1 8
ARID1A, AT-rich interactive domain 1A; ARID1B, AT-rich interactive domain 1B; ASXL1, additional sex combs-like 1; 
CHD8, chromodomain helicase DNA binding protein 8; MLL3, mixed-lineage leukemia protein 3; OCCC, ovarian 
clear cell carcinoma; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase; PPP2R1A, protein phosphatase 2 
regulatory subunit A alpha.
chemoresistance by alteration of glycolytic processes in OCCC cells, and by reducing oxidative 
phosphorylation and thus intracellular reactive oxygen species. Anti-stress properties that allow 
the survival of endometrial cells induce HNF-1β in the microenvironment and this is maintained 
throughout its cell life into malignant proliferation. This conferred stress resistance may 
contribute to the chemoresistance of OCCC [67,68]. PIK3CA mutations play an important role in 
the pathogenesis of OCCC with mutations seen in up to 42% of cases. PIK3CA activation results 
in abnormal cellular growth, proliferation, survival, and angiogenesis via complex intracellular 
networks in the regulation of tumor stem cells. PIK3CA mutations have been associated 
with favourable OS in OCCC in a mutational analysis of 56 primary OCCC cases in Japanese 
women [69-72]. Vascular endothelial growth factor (VEGF) overexpression is commonly seen 
in advanced stage epithelial ovarian cancer and is often associated with a poorer prognosis 
[73,74]. With its critical role in angiogenesis, this overexpression may be a therapeutic target 
and in vitro studies have been promising, showing inhibition of OCCC cell growth especially in 
cisplatin-refractory cases, highlighting its potential role in recurrent disease [75].
3. Controversies in the clinical management of OCCC
Women with OCCC present in early stages, and at a younger age, raising the question of the role 
of cytoreductive vs. fertility sparing surgery. Evidence to support complete surgical staging in 
early stage OCCC is lacking; however, the goal of primary surgical treatment in advanced disease 
should be complete cytoreduction. In the GOG study by Hoskins in 1994, mucinous and clear 
cell subtypes demonstrated a poor outcome despite small residual tumor size even after primary 
cytoreductive surgery [76]. A retrospective analysis of 254 patients showed that only primary 
cytoreduction which was complete contributed to a better in advanced cases [77]. On a similar 
note, the role of lymphadenectomy from a therapeutic perspective is unclear. It is acknowledged 
that the presence of lymph node metastases is an independent prognostic factor however it is 
not associated with OS on multivariate analysis [78-82]. Importantly, women undergoing fertility 
sparing surgery in OCCC did not show poorer survival than their non-OCCC counterparts [83-87].
OCCC demonstrates a lower response rate to platinum based chemotherapy compared to 
HGSC, with response rates of 11%–56% compared to 73%–81% in serous subtypes [77]. 
The Japanese Gynecologic Oncology Group (JGOG) undertook a randomized phase III trial 
(JGOG3017) of paclitaxel/carboplatin versus irinotecan/cisplatin as first-line chemotherapy in 
patients with stage IC–IV OCCC which showed no significant difference in 2-year PFS or OS 
[88], suggesting the need for an alternative approach such as targeted therapy.
4. Take home message
There are still significant gaps in our understanding of OCCC. The effect of hormonal 
status on malignant transformation is incompletely understood and the risks of subsequent 
malignancy in women with endometriosis remains unclear. A number of international 
trials have been designed with the aim of identifying molecular targets; however, it is 
acknowledged that the presence of such targets may not translate into the effectiveness of 
agents used to target them. Adequately powered trials with novel designs will be necessary to 
provide improved clinical outcomes for patients with these rare tumors.
CONCLUSION
Designing adequately powered studies to perform large scale randomized trials is the single 
largest barrier in improving understanding of rare epithelial ovarian cancers. International 
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collaboration with multidisciplinary and translational components through groups such as the 
GCIG is required. Multiple smaller trials which screen agents for activity should be considered in 
the first instance, with expansion into larger randomized trials for agents that show promising 
activity. Additionally, the poor prognosis associated with many of these rare cancers at advanced 
stages signify the need for further research in developing novel methods for screening.
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